Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | BCR | P11274 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665847 | 0.92 | ABL1 (0.51) | ABL1BCRPIK3CAPIK3R1EPHX2 | |
| SCHEMBL4663979 | 0.89 | ABL1 (0.50) | ABL1BCREPHX2METAXL | |
| SCHEMBL4666158 | 0.88 | ABL1 (0.46) | ABL1BCRPIK3CAPIK3R1MAPK14 | |
| SCHEMBL4667480 | 0.85 | ABL1 (0.51) | ABL1BCREPHX2 | |
| SCHEMBL4663917 | 0.85 | ABL1 (0.48) | ABL1BCRAXLRET | |
| SCHEMBL4665611 | 0.84 | ABL1 (0.49) | ABL1BCREPHX2RET | |
| SCHEMBL4664319 | 0.83 | ABL1 (0.46) | ABL1BCRPIK3CAPIK3R1TP53 | |
| SCHEMBL4664349 | 0.82 | ABL1 (0.51) | ABL1BCRMAPK14 | |
| SCHEMBL4663770 | 0.82 | USP2 (0.51) | ABL1BCRTP53 | |
| SCHEMBL4664333 | 0.81 | TP53 (0.49) | ABL1BCRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | ABL1 24/4885BCR 402/4885PIK3CA 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.